Jen-Sheng Pei1, Wen-Shin Chang2, Pei-Chen Hsu1, Yi-Wen Hung3, Shun-Ping Cheng4, Chia-Wen Tsai5, DA-Tian Bau5,6,7, Chi-Li Gong8. 1. Department of Pediatrics, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, R.O.C. 2. Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C. 3. Department of Medicine Research, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C. 4. Department of Physical Medicine and Rehabilitation, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, R.O.C. 5. Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C. datian@mail.cmuh.org.tw artbau2@gmail.com. 6. Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C. 7. Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C. 8. Department of Physiology, China Medical University, Taichung, Taiwan, R.O.C. datian@mail.cmuh.org.tw artbau2@gmail.com.
Abstract
BACKGROUND/AIM: Accumulated evidence has supported the notion that matrix metalloproteinase (MMP) genotypes are associated with the susceptibility of many types of cancers. However, few reports have studied the contribution of MMP genotypes to either diagnostic or prognostic potential in non-solid tumors such as leukemia. In this study, we firstly investigated the contribution of a polymorphism in the promoter region of MMP-8 (-799C/T) and two non-synonymous polymorphisms (Val436Ala and Lys460Thr) to childhood leukemia. PATIENTS AND METHODS: In this study, 266 patients with childhood acute lymphoblastic leukemia (ALL) and 266 non-cancer control patients were collected and the genomic DNA was isolated from their peripheral blood. MMP-8 -799C/T, Val436Ala and Lys460Thr polymorphic genotypes of each subject were determined by the typical polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS: The results showed that the three polymorphisms were not significantly associated with an increased risk of childhood ALL in the overall investigated population. Furthermore, when the analyses were stratified by age and gender, no significant association between these genotypes and increased ALL risk was found. CONCLUSION: Our findings suggest that the polymorphisms at MMP-8 -799C/T, Val436Ala and Lys460Thr may not play a major role in determining the personal susceptibility to childhood ALL in Taiwan. Copyright
BACKGROUND/AIM: Accumulated evidence has supported the notion that matrix metalloproteinase (MMP) genotypes are associated with the susceptibility of many types of cancers. However, few reports have studied the contribution of MMP genotypes to either diagnostic or prognostic potential in non-solid tumors such as leukemia. In this study, we firstly investigated the contribution of a polymorphism in the promoter region of MMP-8 (-799C/T) and two non-synonymous polymorphisms (Val436Ala and Lys460Thr) to childhood leukemia. PATIENTS AND METHODS: In this study, 266 patients with childhood acute lymphoblastic leukemia (ALL) and 266 non-cancer control patients were collected and the genomic DNA was isolated from their peripheral blood. MMP-8-799C/T, Val436Ala and Lys460Thr polymorphic genotypes of each subject were determined by the typical polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS: The results showed that the three polymorphisms were not significantly associated with an increased risk of childhood ALL in the overall investigated population. Furthermore, when the analyses were stratified by age and gender, no significant association between these genotypes and increased ALL risk was found. CONCLUSION: Our findings suggest that the polymorphisms at MMP-8-799C/T, Val436Ala and Lys460Thr may not play a major role in determining the personal susceptibility to childhood ALL in Taiwan. Copyright
Authors: Hongyan Wang; Samuel Parry; George Macones; Mary D Sammel; Pedro E Ferrand; Helena Kuivaniemi; Gerard Tromp; Indrani Halder; Mark D Shriver; Roberto Romero; Jerome F Strauss Journal: Hum Mol Genet Date: 2004-09-14 Impact factor: 6.150
Authors: Patricia González-Arriaga; M Felicitas López-Cima; Ana Fernández-Somoano; Teresa Pascual; Manuel G Marrón; Xose S Puente; Adonina Tardón Journal: BMC Cancer Date: 2008-12-19 Impact factor: 4.430